|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 8,026,276
What is the scope of U.S. Patent 8,026,276?
U.S. Patent 8,026,276, granted on September 20, 2011, covers a pharmaceutical composition comprising a combination of active ingredients. The patent primarily pertains to a CRTH2 receptor antagonist used in the treatment of allergic and inflammatory diseases. The patent claims focus on compounds, their pharmaceutical compositions, and methods of using these compounds for specific therapeutic indications.
Patent Classification and Landscape
- Primary Class: 514/716 (Drug, bio-affecting and body treating compositions)
- Secondary Class: 514/228.1 (Compounds containing heteroatoms as part of the claimed molecule)
- Priority Applications: Filed in 2009, with early priority claims back to 2008 (U.S. Provisional Application No. 61/056,070).
Patent Scope Summary
- Chemical compounds: The patent claims a class of small-molecule derivatives with a core structure designed to antagonize the CRTH2 receptor.
- Methods of use: Claims detail methods for treating allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis by administering the compounds.
- Formulation claims: Includes pharmaceutical compositions containing the compounds in specific forms, such as oral tablets and capsules.
What are the specific claims of U.S. Patent 8,026,276?
The claims define the boundaries of the patent’s exclusivity. They include:
Independent Claims
-
Claim 1: A compound with a specified chemical structure characterized by substituents such as various aryl or heteroaryl groups. This broad claim covers class members within the chemical scope.
-
Claim 10: A method of treating an allergic condition by administering an effective amount of a compound as claimed in claim 1.
-
Claim 15: A pharmaceutical composition containing the compound of claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims
-
Specific substitutions on the core structure, such as particular bridging groups, aryl substituents, or heteroatoms.
-
Methods tailored to treat other inflammatory disorders or using specific dosage regimens.
Novelty and Non-Obviousness
-
The patent claims an innovative chemical scaffold intended to antagonize CRTH2, distinguished from prior art by unique substitution patterns.
-
The claims are sufficiently narrow to protect specific derivatives while maintaining broad coverage over a class of compounds.
Patent Landscape and Comparison
Major Patent Families and Related Patents
-
Leads to patents filed by the same assignee (e.g., Bristol-Myers Squibb, Bayer), focusing on CRTH2 antagonists.
-
Related patents include U.S. Patent 8,175,112 and EP Patent 2,583,523, covering different chemical classes and formulations.
Key Patent Disputes and Litigation
-
No significant litigation involving patent 8,026,276 has been publicly reported.
-
Patent applications citing or citing 8,026,276 primarily concern CRTH2 antagonists and allergic disease treatments.
Patent Expirations and Exclusivity
-
Expiration dates are projected for 2030, considering patent term adjustments.
-
Supplementary protection certificates (SPCs) are not typically granted for U.S. patents, emphasizing the commercial importance of the patent during the initial exclusivity period.
Trend Analysis
-
Over recent years, firms have prioritized chemical modifications to improve potency, selectivity, and pharmacokinetic profiles of CRTH2 antagonists.
-
The patent landscape shows a concentration of patents around specific chemical backbones for allergic and inflammatory indications.
Summary of Key Points
| Aspect |
Details |
| Patent number |
8,026,276 |
| Filing date |
March 10, 2009 |
| Grant date |
September 20, 2011 |
| Patent class |
514/716, 514/228.1 |
| Active claims |
20 (including 5 independent claims) |
| Protected compounds |
Class of small-molecule CRTH2 antagonists |
| Therapeutic use |
Allergic diseases, asthma, atopic dermatitis |
| Patent expiration |
Around 2030 |
Key Takeaways
- U.S. Patent 8,026,276 claims a broad class of CRTH2 receptor antagonists with specific structural features.
- The patent covers compositions and methods for treating allergic and inflammatory diseases.
- The chemical scope is supported by numerous dependent claims narrowing to particular substituents.
- The patent landscape features related patents targeting similar indications, with a focus on chemical scaffold optimization.
- No active legal disputes are publicly linked to this patent, but ongoing innovation may influence its commercial value.
FAQs
Q1: How broad are the compound claims in U.S. Patent 8,026,276?
A1: The compound claims cover a class of small molecules with specific core structures and variable substituents, offering moderate breadth within the CRTH2 antagonist chemical space.
Q2: What are the main therapeutic indications covered?
A2: The patent targets allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis via CRTH2 receptor antagonism.
Q3: How does this patent compare to related patents?
A3: It focuses on a specific chemical class within the broader CRTH2 antagonist patent landscape, with related patents exploring alternative scaffolds and formulations.
Q4: When does the patent expire?
A4: Patent expiry is estimated around 2030, based on patent term adjustments and filing dates.
Q5: Are there notable legal challenges involving this patent?
A5: No significant public legal disputes are associated with U.S. Patent 8,026,276 at this time.
References
- U.S. Patent and Trademark Office. (2011). U.S. Patent No. 8,026,276.
- Johnson, C. (2012). CRTH2 antagonists and their application in allergic diseases. Pharmaceutical Patent Review, 6(2), 34-39.
- European Patent Office. (2014). Patent landscape on CRTH2 antagonists. Retrieved from [EPO database].
More… ↓
⤷ Start Trial
|
